Research & Development

Cambrex to buy Halo Pharma for $425m

Cambrex has agreed to acquire contract development and manufacturing organization (CDMO) Halo Pharma for about $425m.

Novartis to pay EUR95m to Galapagos and MorphoSys for skin drug rights

Novartis has agreed to make an upfront payment of EUR95m to Galapagos and MorphoSys to in-license IL-17C compound for atopic dermatitis.

Otsuka Pharmaceutical to buy biotechnology firm Visterra for $430m

Otsuka Pharmaceutical has agreed to acquire clinical-stage biotechnology firm Visterra for around $430m.

BioCryst terminates merger deal with Idera Pharmaceuticals

BioCryst Pharmaceuticals has failed to get approval from the stockholders for its merger deal with Idera Pharmaceuticals.

Amryt secures funding approval from NHS England for bad cholesterol treatment

Biopharmaceutical firm Amryt has secured approval for funding from NHS England for its bad cholesterol treatment, Lojuxta (lomitapide).

Axovant, Benitec sign licensing deal for AXO-AAV-OPMD program

Axovant Sciences has entered into a global licensing agreement with Benitec Biopharma for BB-301 (AXO-AAV-OPMD) platform to treat oculopharyngeal muscular dystrophy (OPMD).

Catalent to buy Juniper Pharmaceuticals in $133m deal

US-based Catalent has agreed to acquire Juniper Pharmaceuticals in a deal valued at around $133m.

Aveo, Novartis scrap $326m antibody licensing deal

US-based Aveo Pharmaceuticals and Swiss drugmaker Novartis have scrapped their $326m worth licensing agreement to develop and commercialize the former’s humanized inhibitory antibody AV-380 and other related antibodies.

TRIGR Therapeutics, ABL Bio collaborate on next generation therapeutic antibodies

TRIGR Therapeutics and ABL Bio have entered into a binding agreement for TRIGR to license the global commercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer.